<DOC>
	<DOCNO>NCT00908687</DOCNO>
	<brief_summary>This Phase 2 , randomize , blind , clinical trial . Up 500 eligible subject enrol randomized 1:2:2:1:2:2 ratio one six group , vaccinate study . Subjects receive intramuscular injection influenza A/H5N1 ( low high dose ) Day 0 without patch ( low high dose ) .</brief_summary>
	<brief_title>A/H5N1/LT Dose Ranging Study</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult male females 18 49 year age ( inclusive ) Signed Informed Consent Women postmenopausal surgically sterile must negative serum urine pregnancy test screening within 24 hour vaccination understanding ( informed Consent process ) become pregnant duration study , must agree employ effective form birth control duration study . Acceptable form birth control : abstinence , hormonal contraceptive ( oral , injectable , implant , patch , ring ) , doublebarrier contraceptive ( condom diaphragm , spermicide ) IUD Clinically significant laboratory abnormality screen Abnormalities physical examination [ determine Toxicity Grading Scale ( grade 14 ) ] Known allergy component vaccine Known egg protein allergy Known allergy adhesives Known disturbance coagulation Participated research involve investigational product within 45 day plan date vaccination Donated receive blood blood product plasma within past 45 day Received licensed vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior plan date vaccination Ever receive investigational enterotoxigenic E. coli , LT ( R192G ) NasalFlu , Berna Biotech Ltd Ever receive cholera toxin vaccine ( e.g . Orochol , Dukoral ) History abdominal surgery ( exclude CSection , hysterectomy , cosmetic surgery , liposuction , appendectomy , cholecystectomy , ventral hernia repair , surgery pertain gastrointestinal problem ) history , recent acute gastrointestinal ( GI ) illness Previous vaccination pandemic vaccine previous prove contact A/H5N1 wild type virus ( contact individual laboratoryconfirmed A/H5N1 infection contact animal die result A/H5N1 infection ) Recent regular use oral , topical inject steroid medication within 45 day prior vaccination Use immunosuppressive systemic steroid medication include inhaled steroid within three month prior vaccination Comorbid condition treatment immunosuppressive , include cancer , diabetes , endstage renal disease , determine Investigator Positive serology HIV1 , HIV2 , HBsAg , HCV History severe atopy Medical history acute chronic skin disease vaccination area Active skin allergy Signs acute skin infection , sunburn skin abnormality vaccination area include fungal infection , severe acne , active contact dermatitis , history keloid formation Hirsute ( significant amount hair ) vaccination area Artificial tanning ( UV radiation ) duration study include screen period Visible tattoo mark ( tattoos/scars ) vaccination area would prevent appropriate dermatologic monitoring vaccination site Fever great equal 38.0°C ( 100.4°F ) time plan vaccination Suspicion recent history ( within one year plan vaccination ) alcohol substance abuse Women pregnant breastfeed Acute illness screen baseline Ever serious reaction prior influenza vaccination Developed neurological disorder ( Guillian Barré syndrome ) six week follow previous influenza vaccination Medical history achlorhydria Employee investigational site sponsor History employment bird poultry industry considerable exposure bird ( e.g . poultry avian veterinarian , bird breeder , poultry butcher and/or culler , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>